Beam Therapeutics Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Beam Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $7.52M, a 328.66% increase year-over-year.
- Beam Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $2.02M, a 181.64% increase year-over-year.
- Beam Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $412.00K, a 72.38% increase year-over-year.
- Beam Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $1.75M, a 631.25% increase year-over-year.
- Beam Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $4.77M, a 14.79% decline from fiscal 2024.
- Beam Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $5.60M, a 8.66% decline from fiscal 2023.
- Beam Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $6.13M, a 124.41% increase from fiscal 2022.
- Beam Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $2.73M, a 71.62% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $7.52M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $2.02M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $4.77M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $412.00K 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.75M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $719.00K 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $5.60M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $239.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $240.00K 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $1.68M 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $6.13M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $1.29M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $702.00K 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $3.39M 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $2.73M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $502.00K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $646.00K 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $820.00K 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $9.63M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $1.82M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $4.08M 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $1.76M 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $3.15M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $557.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $360.00K 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $152.00K 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $185.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $81.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $48.00K 10-Q · filed 2020-11-10 | |
| 2019-03-31 | $7.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |